O	0	9	Fertility
O	10	22	preservation
O	23	27	with
B-intervention	28	35	ovarian
I-intervention	36	47	stimulation
O	48	51	and
O	52	56	time
O	57	59	to
O	60	69	treatment
O	70	72	in
O	73	78	women
O	79	83	with
O	84	89	stage
O	90	92	II
O	92	93	-
O	93	96	III
O	97	103	breast
O	104	110	cancer
O	111	120	receiving
O	121	132	neoadjuvant
O	133	140	therapy
O	140	141	.

O	142	144	To
O	145	154	determine
O	155	162	whether
O	163	172	fertility
O	173	185	preservation
O	186	190	with
O	191	198	ovarian
O	199	210	stimulation
O	211	212	(
O	212	214	OS
O	214	215	)
O	216	223	results
O	224	226	in
O	227	236	treatment
O	237	242	delay
O	243	245	in
O	246	252	breast
O	253	259	cancer
O	260	261	(
O	261	263	BC
O	263	264	)
O	265	273	patients
O	274	283	receiving
O	284	295	neoadjuvant
O	296	303	therapy
O	304	305	(
O	305	308	NAT
O	308	309	)
O	309	310	.

O	311	315	This
O	316	318	is
O	319	320	a
O	321	334	retrospective
O	335	340	study
O	341	343	of
O	344	349	women
O	350	358	screened
O	359	362	for
O	363	366	the
O	367	378	prospective
O	379	390	neoadjuvant
O	391	396	ISPY2
O	397	402	trial
O	403	405	at
O	406	409	the
O	410	420	University
O	421	423	of
O	424	434	California
B-location	435	438	San
I-location	439	448	Francisco
O	448	449	.

O	450	453	All
O	454	462	patients
O	463	467	were
B-age	468	469	<
I-age	469	471	43
O	471	472	,
B-eligibility	473	476	had
I-eligibility	477	482	stage
I-eligibility	483	485	II
I-eligibility	485	486	-
I-eligibility	486	489	III
I-eligibility	490	492	BC
I-eligibility	492	493	,
I-eligibility	494	497	and
I-eligibility	498	506	received
I-eligibility	507	518	neoadjuvant
I-eligibility	519	526	therapy
O	526	527	.

O	528	532	Time
O	533	535	to
O	536	546	initiation
O	547	549	of
O	550	553	NAT
O	554	557	was
O	558	566	compared
O	567	574	between
O	575	580	women
O	581	584	who
O	585	594	underwent
O	595	597	OS
O	598	599	(
O	599	603	STIM
O	603	604	)
O	605	608	and
O	609	614	women
O	615	618	who
O	619	622	did
O	623	626	not
O	627	628	(
O	628	635	control
O	635	636	)
O	636	637	.

O	638	645	Patient
O	646	649	and
O	650	655	tumor
O	656	671	characteristics
O	671	672	,
O	673	675	as
O	676	680	well
O	681	683	as
O	684	693	oncologic
O	694	702	outcomes
O	702	703	,
O	704	708	were
O	709	717	compared
O	718	725	between
O	726	730	STIM
O	731	734	and
O	735	742	control
O	743	749	groups
O	749	750	.

B-total-participants	751	753	82
O	754	762	patients
O	763	767	were
O	768	776	included
O	777	778	(
B-intervention-participants	778	780	34
O	781	785	STIM
O	786	789	and
B-control-participants	790	792	48
B-control	793	800	control
O	800	801	)
O	801	802	.

O	803	807	STIM
O	808	816	patients
O	817	821	were
O	822	829	overall
O	830	837	younger
O	838	839	(
O	839	843	mean
O	844	845	=
O	846	848	35
O	849	851	vs
O	851	852	.
O	853	855	36
O	855	856	.
O	856	857	9
O	858	863	years
O	864	867	old
O	867	868	,
O	869	870	p
O	871	872	=
O	873	874	0
O	874	875	.
O	875	877	06
O	877	878	)
O	878	879	,
O	880	883	and
O	884	888	more
O	889	895	likely
O	896	898	to
O	899	901	be
O	902	911	childless
O	912	913	(
O	913	915	79
O	915	916	.
O	916	917	4
O	918	920	vs
O	921	923	31
O	923	924	.
O	924	925	2
O	925	926	%
O	926	927	,
O	928	929	p
O	930	931	<
O	932	933	0
O	933	934	.
O	934	938	0001
O	938	939	)
O	940	944	than
O	945	953	controls
O	953	954	.

B-outcome	955	959	Mean
I-outcome	960	964	time
I-outcome	965	969	from
I-outcome	970	979	diagnosis
I-outcome	980	982	to
I-outcome	983	993	initiation
I-outcome	994	996	of
I-outcome	997	1000	NAT
O	1001	1004	was
O	1005	1007	40
O	1008	1012	days
O	1012	1013	,
O	1014	1018	with
O	1019	1021	no
O	1022	1033	significant
O	1034	1044	difference
O	1045	1052	between
O	1053	1057	STIM
O	1058	1061	and
O	1062	1069	control
O	1070	1076	groups
O	1077	1078	(
O	1078	1082	mean
B-iv-cont-mean	1083	1085	39
I-iv-cont-mean	1085	1086	.
I-iv-cont-mean	1086	1087	8
I-iv-cont-mean	1088	1092	days
O	1093	1095	vs
B-cv-cont-mean	1096	1098	40
I-cv-cont-mean	1098	1099	.
I-cv-cont-mean	1099	1100	9
I-cv-cont-mean	1101	1105	days
O	1105	1106	,
O	1107	1108	p
O	1109	1110	=
O	1111	1112	0
O	1112	1113	.
O	1113	1115	75
O	1115	1116	)
O	1116	1117	.

B-outcome	1118	1122	Mean
I-outcome	1123	1127	time
I-outcome	1128	1132	from
I-outcome	1133	1142	diagnosis
I-outcome	1143	1145	to
I-outcome	1146	1155	fertility
I-outcome	1156	1168	consultation
O	1169	1172	was
O	1173	1175	16
O	1175	1176	.
O	1176	1177	3
O	1178	1182	days
O	1182	1183	.

O	1184	1188	With
O	1189	1195	median
O	1196	1202	follow
O	1202	1203	-
O	1203	1205	up
O	1206	1208	of
O	1209	1211	79
O	1212	1218	months
O	1218	1219	,
O	1220	1222	16
O	1223	1224	(
O	1224	1226	19
O	1226	1227	.
O	1227	1228	5
O	1228	1229	%
O	1229	1230	)
O	1231	1239	patients
O	1240	1244	have
B-outcome	1245	1253	recurred
I-outcome	1254	1256	or
I-outcome	1257	1261	died
I-outcome	1262	1266	from
I-outcome	1267	1269	BC
O	1269	1270	.

B-outcome	1271	1276	Rates
I-outcome	1277	1279	of
I-outcome	1280	1283	pCR
O	1283	1284	,
B-outcome	1285	1295	recurrence
O	1295	1296	,
O	1297	1300	and
B-outcome	1301	1306	death
O	1307	1311	were
O	1312	1319	similar
O	1320	1322	in
O	1323	1327	both
O	1328	1334	groups
O	1334	1335	.

B-iv-bin-abs	1336	1339	Six
O	1340	1342	of
B-intervention-participants	1343	1345	34
O	1346	1350	STIM
O	1351	1359	patients
O	1360	1364	have
B-outcome	1365	1374	undergone
I-outcome	1375	1381	embryo
I-outcome	1382	1390	transfer
O	1390	1391	,
O	1392	1401	resulting
O	1402	1404	in
O	1405	1408	one
O	1409	1416	patient
O	1417	1421	with
O	1422	1425	two
O	1426	1430	live
O	1431	1437	births
O	1437	1438	.

O	1439	1448	Fertility
O	1449	1461	preservation
O	1462	1466	with
O	1467	1469	OS
O	1470	1473	can
O	1474	1476	be
O	1477	1486	performed
O	1487	1489	in
O	1490	1493	the
O	1494	1505	neoadjuvant
O	1506	1513	setting
O	1514	1521	without
O	1522	1527	delay
O	1528	1530	in
O	1531	1541	initiation
O	1542	1544	of
O	1545	1553	systemic
O	1554	1561	therapy
O	1562	1565	and
O	1566	1572	should
O	1573	1575	be
O	1576	1585	discussed
O	1586	1590	with
O	1591	1594	all
O	1595	1600	early
O	1600	1601	-
O	1601	1606	stage
O	1607	1609	BC
O	1610	1618	patients
O	1619	1621	of
O	1622	1634	reproductive
O	1635	1638	age
O	1638	1639	.
